Introduction {#s1}
============

Parkinson\'s disease (PD) is the second-most common neurodegenerative disease, with major clinical features comprising motor symptoms (MS) and non-motor symptoms (NMS). MS are characterized by four cardinal symptoms: bradykinesia, resting tremor, rigidity, and postural instability. NMS include olfactory dysfunction, constipation, depression, and sleep disturbance (Konno et al., [@B44]). Levodopa (L-dopa) is a classic treatment for parkinsonism; however, this drug is known to induce motor complications, such as dyskinesia and motor fluctuations that may affect the quality of life of PD patients (Olanow and Stocchi, [@B59]; Picconi et al., [@B67]).

In recent times, the pathogenesis of PD often remains unclear. Genetic factor, environmental factor and aging all contribute to PD pathogenesis (Liu et al., [@B51]; Yan et al., [@B90]; Zhang et al., [@B92]). Leucine-rich repeat kinase 2 (*LRRK2*) is considered the most common genetic cause of PD (Paisan-Ruiz, [@B62]; Guo et al., [@B31]; Li et al., [@B50]); an increasing number of studies have focused on the genotype and phenotype analysis of *LRRK2* and PD. Whether the clinical features of *LRRK2*-associated PD differ from those of idiopathic PD (IPD) is still debatable. Some researchers believe that *LRRK2*-related PD has similar clinical onset features to IPD, such as resting tremor, good response to L-dopa, and a benign clinical course (Orr-Urtreger et al., [@B61]; Paisan-Ruiz, [@B62]; Zheng et al., [@B94]). However, others have reported that *LRRK2*-related PD has distinct features that differ from those of IPD and vary between different genotypes (Marras et al., [@B53]). For example, original studies have reported that G2019S carriers are more likely to be women, less likely to develop olfactory dysfunction, and more likely to have dyskinesia and dystonia than non-carriers (Marras et al., [@B53]). G2385R carriers have been observed to exhibit a tendency toward motor fluctuations and are more likely to have postural instability gait disorder phenotype (Oosterveld et al., [@B60]). Additionally, some researchers carried out analyses of *LRRK2*-associated clinical features by combining different variants, without considering the different clinical features among the different variants (Paisan-Ruiz et al., [@B63]). Considering the heterogeneous risk of *LRRK2* variants in PD, it is thus vital to provide evidence, via pooled analysis, to identify specific *LRRK2* variants associated with clinical phenotypes.

Our previous comprehensive meta-analysis demonstrated the importance of *LRRK2* SNPs, such as G2385R, G2019S, R1628P in PD (data unpublished). To further explore the role of *LRRK2* SNPs in PD clinical features, here, we conducted a complete analysis of clinical features in specific *LRRK2* variants related to PD.

Methods {#s2}
=======

Literature search
-----------------

Medline database in PubMed, Embase database in Ovid, and the Cochrane databases were electronically searched by the authors for publications in English. The key words used were "Parkinson^\*^," "PD," "*LRRK2*," and "PARK8." The data were assessed online on February 10, 2018. Overlapping articles from different databases were excluded. Two researchers (Li Shu and Yuan Zhang) performed the search independently. In case of disagreements, a third researcher (Qiying Sun) was consulted to arrive at a consensus.

Selection criteria
------------------

The PICOS (participants, interventions, controls, outcomes, and study types) principle was applied in the inclusion process.

Participants: all PD patients were diagnosed according to widely accepted criteria (Hughes et al., [@B36]) and carried specific *LRRK2* variants.

Interventions: genetic analyses were conducted using genomic DNA by PCR-based methods or other accepted methods.

Controls: controls were PD patients without specific *LRRK2* variants.

Outcomes: available data to calculate the number of carriers and non-carriers of the responsive phenotypes.

Study types: original case only study, case-control study, or cohort study.

Data extraction
---------------

Complete data including first author, publication year, ethnicity, country, gene, variants, numbers of cases, and their responsive clinical features were extracted by two researchers (Li Shu and Yuan Zhang). If there were disputes in the process, a third author was asked to solve the problem (Qiying Sun; Table [1](#T1){ref-type="table"}; Supplementary Table [1](#SM1){ref-type="supplementary-material"}). The process of data extraction is shown in the flowchart (Figure [1](#F1){ref-type="fig"}). Briefly, we included studies that defined age at onset ≤ 50 years as early-onset PD (EOPD) and age at onset \>50 years as late-onset PD (LOPD).

###### 

The publications included for phenotype analysis.

  **References**                    **Ethnicity**          **Country**                  **Variants**     **No. patients**
  --------------------------------- ---------------------- ---------------------------- ---------------- ------------------
  Bras et al., [@B8]                European/West Asians   Portugal                     G2019S           128
  Lesage et al., [@B48]             Africans               North Africa                 G2019S           106
  Gaig et al., [@B24]               European/West Asians   Spain                        G2019S           302
  Di Fonzo et al., [@B18]           East Asians            China                        G2385R           608
  Goldwurm et al., [@B29]           European/West Asians   Italy                        G2019S           1,092
  Kay et al., [@B41]                Mixed                  America                      G2019S           1,518
  Clark et al., [@B13]              Mixed                  America                      G2019S           504
  Ishihara et al., [@B38]           Africans               Tunis                        G2019S           201
  Fung et al., [@B23]               East Asians            Taiwan                       G2385R           305
  Farrer et al., [@B20]             East Asians            Taiwan                       G2385R           410
  Tan et al., [@B81]                East Asians            Singapore                    G2385R           62
  Funayama et al., [@B22]           East Asians            Japan                        G2385R           448
  Orr-Urtreger et al., [@B61]       European/West Asians   Israel                       G2019S           344
  Li et al., [@B49]                 East Asians            China                        G2385R           235
  An et al., [@B4]                  East Asians            China                        G2385R           600
  Gan-Or et al., [@B26]             European/West Asians   Israel                       G2019S           128
  Chan et al., [@B12]               East Asians            China                        G2385R           34
  Hulihan et al., [@B37]            Africans               Tunis                        G2019S           238
  Pankratz et al., [@B65]           Mixed                  North America                G2019S           840
  Mata et al., [@B55]               Hispanics              Peru,Uruguay                 G2019S,R1441C    360
  Lesage et al., [@B47]             Africans               North Africa                 G2019S           136
  Latourelle et al., [@B46]         Mixed                  America                      G2019S,R1441C    1,025
  Gan-Or et al., [@B26]             European/West Asians   Isreal                       G2019S           477
  Zhang et al., [@B93]              East Asians            China                        R1628P           600
  Yu et al., [@B91]                 East Asians            China                        R1628P           328
  Kim et al., [@B43]                East Asians            Korea                        G2385R           923
  Alcalay et al., [@B2]             Mixed                  America                      G2019S           691
  Belarbi et al., [@B5]             Africans               Algeria                      G2019S           106
  Shanker et al., [@B76]            European/West Asians   Isreal                       G2019S           42
  Hashad et al., [@B32]             Africans               Egypt                        G2019S           113
  Saunders-Pullman et al., [@B75]   Mixed                  Israel and America           G2019S           61
  Marras et al., [@B54]             Mixed                  Canada, Germany and Brazil   G2019S           109
  Ben Sassi et al., [@B6]           Africans               Tunis                        G2019S           110
  Yahalom et al., [@B87]            European/West Asians   Israel                       G2019S           349
  Yan et al., [@B89]                East Asians            China                        G2385R           354
  Fu et al., [@B21]                 East Asians            China                        G2385R, R1628P   446
  Sierra et al., [@B77]             European/West Asians   Spain                        G2019S           79
  Gatto et al., [@B28]              Hispanics              Argentina                    G2019S           55
  Cai et al., [@B10]                East Asians            China                        G2385R, R1628P   510
  Tijero et al., [@B82]             European/West Asians   Spain                        G2019S, R1441C   19
  Greenbaum et al., [@B30]          European/West Asians   Israel                       G2019S           39
  Gao et al., [@B27]                East Asians            China                        G2385R           175
  Mirelman et al., [@B57]           European/West Asians   Israel                       G2019S           100
  Alcalay et al., [@B3]             Mixed                  Israel and America           G2019S           488
  Trinh et al., [@B83]              Africans               Tunis                        G2019S           570
  Yahalom et al., [@B88]            European/West Asians   Israel                       G2019S           405
  Pulkes et al., [@B68]             East Asians            Thailand                     R1628P           485
  Estanga et al., [@B19]            European/West Asians   Spain                        R1441G           60
  Gaig et al., [@B25]               European/West Asians   Spain                        G2019S           66
  Alcalay et al., [@B1]             Mixed                  MJFF center                  G2019S           236
  Nabli et al., [@B58]              Africans               Tunis                        G2019S           58
  Saunders-Pullman et al., [@B73]   Mixed                  America or Israel            G2019S           252
  Somme et al., [@B79]              European/West Asians   Spain                        G2019S, R1441C   54
  Marder et al., [@B52]             Mixed                  MJFF center                  G2019S           474
  Vilas et al., [@B84]              European/West Asians   Spain                        G2019S           57
  Saunders-Pullman et al., [@B71]   Mixed                  America                      G2019S           286
  Marras et al., [@B53]             Mixed                  MJFF center                  G2019S, G2385R   1,602
  Sun et al., [@B80]                East Asians            China                        G2385R           301
  Dagan et al., [@B16]              European/West Asians   Israel                       G2019S           211
  Cao et al., [@B11]                East Asians            China                        G2385R           68
  Pal et al., [@B64]                Mixed                  CORE-PD                      G2019S           76
  Hong et al., [@B35]               East Asians            Korea                        G2385R           299
  Bouhouche et al., [@B7]           Africans               Morocco                      G2019S           100
  da Silva et al., [@B15]           Hispanics              Brazil                       G2019S           110
  San Luciano et al., [@B70]        Mixed                  MJFF center                  G2019S           1,289
  Saunders-Pullman et al., [@B72]   Mixed                  Israel, USA                  G2019S           545

![Flowchart showing the literature screening process.](fnagi-10-00283-g0001){#F1}

Statistical analysis
--------------------

Revman 5.3 software was used for all statistical analyses. Pooled odds ratio (ORs) or pooled mean difference (MD) and 95% CIs were calculated to estimate dichotomous data or continuous data about the importance of polymorphisms to the risk of phenotypes. Q statistic and I^2^ statistic indicated heterogeneity of the analysis. If the heterogeneity was not significant (*p* \> 0.1, *I*^2^ \< 50%), a fixed model (FM) was used for further analysis. However, if the heterogeneity was significant (*p* \< 0.1, *I*^2^ \> 50%), a random model (RM) was applied. Publication biases were measured using funnel plots. Sensitivity analyses were performed by eliminating papers one at a time, and the changes in the total results were observed.

Results {#s3}
=======

The selection process and presentation of the final results
-----------------------------------------------------------

A flowchart depicting the publication search process is shown in Figure [1](#F1){ref-type="fig"}. A total of 4,307 articles were retrieved after searching the databases. After excluding 1,080 overlapping articles from different databases as well as 3,161 articles that did not meet the selection criteria, 66 studies comprising 23,402 patients were considered for the final meta-analysis of phenotypes of specific *LRRK2* variants related to PD. Forty-six articles comprising 16,016 patients were included for analysis of the clinical features of *LRRK2*-G2019S-related PD. Seventeen articles involving 6,767 patients were included for analysis of clinical presentations of *LRRK2*-G2385R-related PD; out of these, 5 *LRRK2*-R1628P--related articles comprising 2,369 patients and 5 *LRRK2*-R1441G--related articles comprising 1,222 patients were included in the final meta-analysis. The characteristics of the included studies in each analysis are shown in Table [1](#T1){ref-type="table"}; Supplementary Table [1](#SM1){ref-type="supplementary-material"}. The total results of meta-analyses on these four variants were shown in Table [2](#T2){ref-type="table"}; Supplementary Figure [1](#SM5){ref-type="supplementary-material"}; Supplementary Table [2](#SM2){ref-type="supplementary-material"}. Besides, subgroup analyses of each variant were conducted in different ethnic groups (Africans, European/West Asians, Hispanics, East Asians and Mixed: composed of at least two different groups) according to ethnic classifications by Risch, N et al. (Risch et al., [@B69]; Supplementary Tables [3](#SM3){ref-type="supplementary-material"},[4](#SM4){ref-type="supplementary-material"}; Supplementary Figure [3](#SM7){ref-type="supplementary-material"}).

###### 

The results of phenotype-association analysis of each variant of *LRRK2*.

  **LRRK2 phenotypes or rating scales**        **G2019S**   **G2385R**   **R1628P**   **R1441G**
  -------------------------------------------- ------------ ------------ ------------ ------------
  **DEMOGRAPHIC INFORMATION**                                                         
  Asymmetrical onset                           −            −            NA           NA
  Age at onset                                 −            −            −            NA
  Early onset                                  \+           −            −            NA
  Male                                         \+           −            −            --
  Family history                               \+           \+           NA           NA
  **FIRST SYMPTOMS**                                                                  
  FS-Bradykinesia                              −            −            NA           NA
  FS-Resting tremor                            −            −            −            NA
  FS-Rigidity                                  −            −            NA           NA
  FS-Postural instability or Gait difficulty   −            −            NA           NA
  FS-Dystonia                                  −            NA           NA           NA
  FS-Micrographia                              −            NA           NA           NA
  **MOTOR SYMPTOMS**                                                                  
  Bradykinesia                                 −            NA           NA           NA
  Resting tremor                               −            −            NA           NA
  Rigidity                                     −            −            NA           NA
  Postural instability or gait difficulty      −            NA           NA           NA
  **MOTOR PHENOTYPE CLASSIFICATIONS**                                                 
  T-Akinetic-rigid/PIGD                        −            NA           NA           NA
  T-Mixed/Intermediate                         −            NA           NA           NA
  T-Tremor-dominant                            −            NA           NA           NA
  **SCALES EVALUATING DISEASE SEVERITIES**                                            
  UPDRS I                                      −            −            NA           NA
  UPDRS II                                     −            −            NA           NA
  UPDRS III                                    −            −            NA           --
  H-Y                                          −            \+           −            NA
  Schwab & England                             \+           NA           NA           NA
  **MOTOR COMPLICATIONS**                                                             
  Dyskinesia                                   \+           −            NA           NA
  Motor fluctuations                           \+           \+           NA           NA
  **NEUROPSYCHIATRIC DISTURBANCES**                                                   
  Anxiety                                      −            NA           NA           NA
  Depression                                   −            −            NA           NA
  GDS15                                        \+           NA           NA           NA
  Hallucination                                −            NA           NA           NA
  **AUTONOMIC DISTURBANCES**                                                          
  SCOPA-AUT                                    −            NA           NA           NA
  **COGNITIVE IMPAIRMENTS**                                                           
  Cognitive impairments                        −            NA           NA           NA
  MMSE                                         −            \+           NA           NA
  MoCA                                         −            NA           NA           NA
  **SLEEP DISTURBANCES**                                                              
  Sleep disturbances                           −            NA           NA           NA
  **SENSORY COMPLAINTS**                                                              
  Olfactory disturbances                       −            NA           NA           NA
  UPSIT scores                                 \+           NA           NA           NA
  **TREATMENTS**                                                                      
  Good response to l-dopa                      \+           NA           NA           NA
  LEDD                                         \+           \+           NA           NA
  **ENVIRONMENTAL FACTORS**                                                           
  Smoke                                        \+           NA           NA           NA

*+, clinical symptoms related to a specific variant; −, clinical symptoms not related to a specific variant; NA, not available*.

The clinical characteristics of LRRK2-G2019S carriers
-----------------------------------------------------

In terms of the clinical features of specific variants, the present meta-analysis showed unique clinical manifestations in G2019S, G2385R, R1628P, and R1441G separately. In total, 40 specific clinical features or rating scales belonging to 13 classifications (Park and Stacy, [@B66]) were included in our meta-analysis of G2019S-related clinical characteristics (Table [2](#T2){ref-type="table"}; Supplementary Table [2](#SM2){ref-type="supplementary-material"}).

Our data show that G2019S carriers were predominantly female and had higher rates of EOPD and family history (OR: 0.77 \[male\], 1.37, 2.62; *p* \< 0.00001, 0.02, \< 0.00001). With respect to NMS, G2019S carriers tended to have lower Geriatric Depression Scale (GDS) scores and higher University of Pennsylvania Smell Identification Test (UPSIT) scores than non-carriers (MD: 0.43, 4.70; *p* = 0.01, \< 0.00001). In terms of the response to treatment, the G2019S carriers showed good response to L-dopa (OR: 2.33; *p* \< 0.0001) and higher Schwab and England Activity of Daily Living Scale scores (Schwab & England; MD: 1.49; *p* \< 0.00001). Further, the G2019S carriers received a statistically higher Levodopa equivalent daily dose (LEDD) (MD: 115.20; *p* \< 0.00001) and were more likely to develop motor complications, such as dyskinesia and motor fluctuations than non-carriers (OR: 2.18, 2.02; *p* \< 0.00001, 0.04). Other clinical presentations did not feature G2019S.

In subgroup analyses by ethnicity, in Africans, the higher scores of UPDRSIII, more likely to develop dyskinesia were found in PD patients with G2019S variant than without G2019S variant (MD: 4.79, OR: 2.61; *p*: 0.0005, \< 0.0001). In European/West Asians, the G2019S carriers tended to have earlier age at onset, be female, have higher rates of EOPD, family history and higher LEDD than non-carriers (MD: −2.44, OR: 0.63 \[male\], 1.48, 2.98, MD: 102.43; *p*: 0.001, \< 0.0001, 0.01, \< 0.00001, 0.02). In Hispanics, family history characterized G2019S carriers (OR: 4.66; *p*: 0.0003). In mixed ethnic group, the G2019S carriers were more likely to be female, have family history (OR: 0.77 \[male\], 2.22; *p*: \< 0.00001, \< 0.00001). And the carriers tended to develop akinetic-rigid motor phenotype, dyskinesia, have lower GDS scores, better response to levodopa (l-dopa), higher LEDD and smoking rates (OR: 1.85, 2.37, MD: 0.44, 2.80, 129.87, OR: 1.57; *p*: 0.0007, \< 0.00001, 0.01, \< 0.0001, \< 0.00001, 0.0002). There were not enough data to analyze G2019S-related clinical features in East Asians in PD (Supplementary Tables [3](#SM3){ref-type="supplementary-material"}, [4](#SM4){ref-type="supplementary-material"}).

Clinical characteristics of LRRK2-G2385R carriers
-------------------------------------------------

In total, 20 specific clinical features or rating scales belonging to eight classifications (Park and Stacy, [@B66]) were included in our meta-analysis of G2385R-related clinical characteristics (Table [2](#T2){ref-type="table"}; Supplementary Table [2](#SM2){ref-type="supplementary-material"}). In the analysis of G2385R-related clinical features, we demonstrated that PD patients with G2385R variants were more likely to have family history (OR: 2.10; *p* = 0.007). With respect to the NMS, G2385R carriers had higher Mini Mental State Examination (MMSE) scores than non-carriers (MD: 1.02; *p* = 0.0007). In terms of MS, G2385R carriers had lower Hoehn and Yahr rating (H-Y) than non-carriers (MD: −0.13; *p* = 0.02). In terms of treatment, G2385R carriers received statistically higher LEDD (MD: 53.22; *p* = 0.01) and were more likely to develop motor fluctuations than non-carriers (OR: 3.17; *p* \< 0.00001). In terms of the other clinical features of G2385R, no statistically significant differences were observed between carriers and non-carriers.

In subgroup analyses by ethnicity, in East Asians, the PD patients with G2385R variant tended to have family history, develop motor fluctuations and have higher MMSE scores (OR: 2.1, 3.84, MD: 1.02; *p*: 0.007, \< 0.00001, 0.0007). There were not enough data to analyze G2385R-related clinical features in other ethnic groups in PD (Supplementary Tables [3](#SM3){ref-type="supplementary-material"}, [4](#SM4){ref-type="supplementary-material"}).

The clinical characteristics of LRRK2-R1628P or R1441G carriers
---------------------------------------------------------------

In the analysis of R1628P-related clinical features, we included demographic information, such as age at onset, EOPD rates, sex, first symptoms, such as resting tremor, and H-Y rating. In the analysis of R1441G- related clinical characteristics, gender and UPDRSIII scores were included in the pooled analysis. No significant differences between carriers and non-carriers were observed in terms of the clinical characteristics of R1628P and R1441G. The forest plots of each analysis are shown in Supplementary Figure [1](#SM5){ref-type="supplementary-material"}. There were no positive results of the two variants in subgroup analyses by ethnicity (Supplementary Tables [3](#SM3){ref-type="supplementary-material"}, [4](#SM4){ref-type="supplementary-material"}).

Statistical sensitivity and bias analysis
-----------------------------------------

Articles included in the analysis focused on the relationships between the common polymorphisms and PD phenotypes. Most funnel plots of all analyses were symmetric, which indicated that there was little publication bias in the meta-analysis, except for some phenotypes (Supplementary Figures [2](#SM6){ref-type="supplementary-material"}, [4](#SM8){ref-type="supplementary-material"}). According to the sensitivity analysis, the pooled OR and 95% confidence interval (CI) did not change significantly when deleting each included article one at a time. The pooled OR for each analysis was stable.

Discussion {#s4}
==========

The present meta-analysis was a comprehensive pooled analysis of specific variants in *LRRK2* and their associated clinical features. Detailed genotype and phenotype data were all completely included in the meta-analysis for comprehensive exploration of the important role of *LRRK2* variants in PD risk.

We found that carriers of *LRRK2* variants had distinct clinical features compared with non-carriers. Unique features differed between *LRRK2* variants. In previous studies of *LRRK2*-related PD, researchers characterized *LRRK2*-related clinical features in patients carrying any of the *LRRK2* variants, while ignoring the unique clinical features of each specific variant (Vilas et al., [@B85]; De Rosa et al., [@B17]). For example, De Rosa A et al. considered similar cognitive functions between carriers of *LRRK2* G2019S or R1441G and non-carriers (De Rosa et al., [@B17]). However, studies of specific variants, such as R1441G reported lower likelihood of developing significant cognitive dysfunction than in IPD (Somme et al., [@B79]). Therefore, it is necessary to discuss the unique clinical features of *LRRK2*-related PD based on each specific variant.

With respect to demographic features, G2019S carriers were more likely to be female and have higher rates of EOPD and family history, while G2385R carriers were more likely to have family history. The reason that *LRRK2*-G2019S carriers had a higher rates of family history is that the mutation is a pathogenic non-synonymous amino acid substitution and may be a cause of familial parkinsonism besides its role in sporadic PD as a SNP like G2385R or R1628P (Mata et al., [@B56]). While the heritability of EOPD is high, the carriers of *LRRK2*-G2019S had higher rates of EOPD than non-carriers (Clark et al., [@B13]). The gender differences between *LRRK2*-G2019S carriers and non-carriers in PD may due to a heavier genetic load of female than male in PD as manifested by our analysis. Female who developed PD tended to have higher rates of genetic PD which manifested a higher rates of family history than male (Saunders-Pullman et al., [@B74]). In our previous research of *LRRK2* in PD, we recommended screening for specific race-associated variants, such as G2019S in Caucasian and G2385R in Asian populations (data unpublished). This previous analysis further suggested that specific demographic features, such as female sex, EOPD, or family history may be used to select a targeted population for *LRRK2* screening when conducting or planning research.

Previous research indicated a more benign clinical course of G2019S-related PD compared with that for IPD; for example, lower incidence of falls, dyskinesia, cognition, and olfaction dysfunctions (Healy et al., [@B34]; Haugarvoll and Wszolek, [@B33]; Marras et al., [@B54]). The results of the present pooled analysis were consistent with previous results, in that G2019S carriers tended to have better quality of life as reflected by the Schwab & England scale, are less likely to be depressed, less prone to olfactory dysfunction, and show better response to L-dopa than non-carriers. The present finding that G2019S carriers exhibit less severe olfactory dysfunction was consistent with previous findings showing that abnormal olfaction function was present in up to 49% of patients, which is much lower than in IPD. (Healy et al., [@B34]). Other studies have suggested that *LRRK2*-G2019S is associated with abnormal olfactory function as a result of effects on Lewy body pathology in the rhinencephalon (Silveira-Moriyama et al., [@B78]; Kalia et al., [@B39]). G2385R carriers also presented with consistent benign clinical features, such as lower H-Y rating than non-carriers. With respect to NMS, G2385R carriers were less likely to have cognitive impairments than IPD patients, as reflected by the higher MMSE scores. We also did subgroup analyses by ethnicity and found clinical features of PD patients with *LRRK2* variants especially G2019S and G2385R in specific ethnic groups. Although there were articles discussing about the genotype-phenotype correlations of *LRRK2* in PD (Kestenbaum and Alcalay, [@B42]; Koros et al., [@B45]), our analysis is a pilot study which controlled the race variable and found clinical features of PD with *LRRK2* variants in different ethnic groups.

The impact of pharmacogenetics on the efficacy and side effects of treatment is widely studied in the context of PD therapeutics; susceptible variants or genes have been shown to be associated with the appropriate therapeutic dosage of L-dopa or relevant motor complications. Genetic variants, such as *DRD3* G3127A in the dopamine receptor (DR) gene have been shown to be involved in L-dopa-induced dyskinesia (Comi et al., [@B14]). G2385R in *LRRK2* was previously found to be significantly associated with motor complications in female PD patients (Gao et al., [@B27]). Our analysis demonstrated that G2019S or G2385R carriers tend to develop motor complications with significant differences, consistent with higher LEDD, relative to non-carriers (Cacabelos, [@B9]). As motor complications are known to severely damage the life quality of PD patients, it is our duty, as clinicians, to minimize complications, such as dyskinesia and motor fluctuations. Our results enable deeper understanding of the underlying genetic characteristics of PD by highlighting G2019S or G2385R variants in *LRRK2* as predictors for the development of motor complications, in addition to the well-established factors, such as young age at onset, higher L-dopa dose, and low body weight (Warren Olanow et al., [@B86]). Motor complications should be carefully considered when such patients are treated with high doses of L-dopa.

The present comprehensive analysis provides strong support for the distinct clinical features associated with different *LRRK2* variants, which indicate a phenotype-genotype correlation in PD. There were phenotype-genotype correlations of other PD causative genes, such as *Parkin, PINK1*, and *DJ1*. Besides widely known clinical features of these genes like good treatment response and dyskinesia, systematic review found discrepancies from reviews or original articles. For example, *Parkin* mutation carriers tended to present with late age at onset and not have sleep benefit (Kasten et al., [@B40]). We were additionally able to predict the clinical course of PD in patients with a specific *LRRK2* variant and treat these patients more precisely with early intervention to delay disease progression and control complications. The heterogeneous clinical symptoms for *LRRK2*-G2019S or G2385R-related PD may indicate a distinct pathophysiology in variant carriers; however, the underlying mechanisms remain elusive.

Given the nature of case-control original articles, the present meta-analysis has some inevitable limitations. First, because of the lack of sufficient data and small sample size, we were unable to perform a meta-analysis of the relationship between other widely researched variants, such as A419V and R1398H (data unpublished) and the phenotypes of PD. Therefore, more comprehensive data are needed to perfect this meta-analysis. Second, heterogeneities existed among original studies in our pooled analysis; with a greater availability of original articles, it is advisable to adjust the pooled results and aim for more robust evidence. Third, co-occurrence and interaction between the factors could not be analyzed in the present meta-analysis, which may have confounded the results.

Conclusion {#s5}
==========

Clinical heterogeneity in *LRRK2*-associated PD among different variants, especially for G2019S and G2385R, was found to occur. We observed no distinct clinical features for R1628P or R1441G. The prominent clinical features of *LRRK2-*G2019S-related PD patients were female sex and higher rates of EOPD and family history. Further, G2019S carriers were less likely to be depressive and have olfactory dysfunctions, had better response to L-dopa and better quality of life than non-carriers. Furthermore, carriers tended to be treated with higher dose of L-dopa and were more likely to develop motor complications, such as dyskinesia and motor fluctuations. With respect to the clinical symptoms of G2385R carriers, this group was more likely to have more family history, lower H-Y rating, and was less likely to develop cognitive dysfunctions than non-carriers. High-dose L-dopa treatment and related motor fluctuations were more likely to occur in PD patients carrying the G2385R variant. Other clinical presentations did not feature G2019S or G2385R. No distinct clinical features were found in R1628P or R1441G variants. Our subgroup analyses in different ethnic group also presented with relevant clinical characteristics of PD patients with G2019S and G2385R but not of R1628P or R1441G.
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